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Introduction
The ductal carcinoma in situ (DCIS) of the breast,
identified 70 years ago (1), is a more and more frequent
neoplasia thanks to the screening programs, represen-
ting over 25% of diagnosed breast cancers in recent
surveys (2). It is particularly interesting as concerns se-
veral aspects of which the most important are issues
linked to clinical diagnosis and the difficulties of histo-
pathological classification, with evident and important
therapeutic implications (3-6).
In fact DCIS diagnosis presents some peculiarities
concerning not only its presence but its extension as
well; from this point of view mammography remains
the most reliable diagnostics, though combined with
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Aim. The ductal carcinoma in situ (DCIS) is a more and more fre-
quent neoplasia, representing over 25% of diagnosed breast cancer in
recent surveys.It is particularly interesting as concerns several aspects of
which the most important are issues linked to clinical diagnosis and the
difficulties of histopathological classification, with evident and impor-
tant therapeutic implications.  
Patients and methods. The authors report their experience about
161 ductal carcinoma in situ of the breast. Guidelines for surgical
treatment are: radiological or clinical diagnosis, tumor’s extension, hi-
stological classification, grading and margin status. At the present the
authors prefer breast conserving surgery with tumor margin’s study.
They report their experience in the last seven years about sentinel lymph
node biopsy. 
Results. The most frequent histotype resulted comedocarcinoma
(61,8%) followed by non comedo (38,2%). Local recurrence after
DCIS therapy is 6,1%.
Conclusions. 80-90% of the patients currently treated for DCIS
present non-palpable breast lesions at diagnosis. Breast conserving sur-
gery is the first choice and radiotherapy and endocrine therapy are in-
dicated for selected patients.
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Obiettivo. Il carcinoma duttale in situ (DCIS) rappresenta una
neoplasia sempre più frequente, rappresentando oltre il 25% dei cancri
della mammella osservati in recenti casistiche. Presenta particolare inte-
resse circa alcuni aspetti tra i quali l’approccio clinico e diagnostico e le
difficoltà di classificazione istopatologica con implicazioni terapeutiche.
Pazienti e metodi. Gli Autori riportano la loro esperienza relati-
va a 161 casi di carcinoma duttale in situ. Linee guida per il tratta-
mento chirurgico sono: diagnosi clinica o radiologica, estensione della
neoplasia, classificazione istologica, grading e studio dei margini di se-
zione. L’orientamento attuale è per un trattamento chirurgico conser-
vativo con attento studio dei margini di sezione. Viene anche riporta-
ta l’esperienza degli ultimi 7 anni circa l’impiego della biopsia del
linfonodo sentinella. 
Risultati. L’istotipo più frequente è stato il comedocarcinoma
(61,8%) seguito dalle forme non comedo (38,2%). La recidiva locale
si è attestata intorno all’6,1%.
Conclusioni. L’80-90% delle pazienti trattate per DCIS si pre-
senta alla osservazione senza lesioni palpabili. La chirurgia conservati-
va rappresenta l’opzione di scelta mentre la radioterapia e la endocri-
noterapia sono indicate in casi selezionati.
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echo-guided microbiopsies (Mammotome®). Still to-
day the first problem is the diagnosis of the extension
of disease. The techniques which were proposed to be
carried out together with mammography, didn’t show
particularly effective, including MR with contrast me-
dium (7). 
Aim of this work is to analyse the results of diagno-
stics in homogeneous population of women with
DCIS and compare them with the results of the inter-
national literature, paying particular attention to the
diagnosis of location and extension with current dia-
gnostics, which can lead to the possibility of remaining
disease at the surgical resection margin. 
The other peculiarity of DCIS is the difficulty of
the surgical and metasurgical treatment. If the para-
digm according to which mastectomy cancels the pos-
sibility of DCIS relapse (of which 50% is penetrating)
is true, then it is also true that it sounds contradictory
thinking that it’s possible to treat the penetrating types
with conservative surgery and those in situ with radical
surgery (8, 9). The problem lies fundamentally in the
difficulty of diagnosis of multifocal and multicentric
lesions and because DCIS looks like a group of disea-
ses with different degrees of development and aggressi-
veness. Hence, the therapy may require an appropriate
“tailoring” depending on the histological and immu-
nohistochemical findings. 
Patients and methods
From January 2001 to January 2007 we treated 161 DCIS (97
in Naples and 64 in Terni) in women aged between 28 and 71 years
(mean 51,4). DCIS was diagnosed in 28 women for a palpable
mass (2,2 cm) with or without nipple bleeding, in 3 cases only for
hemorrhagic secretion and in 130 cases for the presence of micro-
calcifications at the mammography, with or without other altera-
tions which could be pointed out by radiological exam or echo-
graphy. In 28 patients with palpable mass fine needle cytology was
suspicious in 19 and not indicative in 9 patients. In the group of
130 patients without palpable mass fine needle cytology was carried
in 51 patients (correct diagnosis in 35 patients), core biopsy in 29
patients (4 false negative), echo-guided Mammotome® in 34 pa-
tients and surgical biopsy for other reasons in 17 patients. Excisio-
nal biopsy with metallic guide or with ROLL was carried in 101 pa-
tients to confirm diagnosis. 
All the women underwent surgical treatment which consisted
in lumpectomy in 11 cases, quadrantectomy in 133 and mastec-
tomy in 17. The mastectomy was a simple one in 16 cases, skin-spa-
ring in 2 and nipple-sparing mastectomy in 3. In 5 cases, due to the
observation of involved margins after quadrantectomy, a following
mastectomy was necessary. The treatment of axillary lymph nodes
was also different as 2 case received no treatment, in 114 cases only
the sentinel node biopsy (SNB) was carried out, and 45 women had
the axillary sampling. The main indication which led to lymphec-
tomy (SNB or sampling) was either the presence of a palpable mass
or extended DCIS or G3-type comedonic DCIS. In 6 (5,1%) cases
the histological exam showed the presence of lymphonodal meta-
stasis (the only sentinel node).
Results
The most frequent histotype resulted comedocarci-
noma (99 cases, 61,8%), followed by non comedo (62
cases, 38,2%). In some cases we observed of different
histotypes at the same time. However we excluded
from this work the DCIS cases with microinvasion. As
for the nuclear ratio we observed differences in histoty-
pes present at the same time.
The hormone receptors resulted positive in 128 ca-
ses; the positivity of c-erb was noticed in 10 cases.
The adjuvant treatment was modulated considering
various elements:
- palpable mass or DCIS XR and its extension;
- histotype and nuclear ratio;
- free margins;
- chemotherapy (used only for one patient with
metastasis at the sentinel node).
On the basis of these factors, the adjuvant radiothera-
pic treatment was proposed to the women having high-
degree comedonic DCIS with palpable mass or widely
extended.
At 3,7 year average follow-up, we observed 10
(6,1%) relapses of which 5 penetrating type, still found
in women who underwent conservative surgery. The
relapse arose in the same quadrant in 4 and in different
quadrants of the same breast in 2 cases, at time interval
variable between 1 and 6 years. In one case the relapse
arose one year after the operation in the retroareolar
ducts of the right breast in a woman who had gone th-
rough menopause and had bilateral nipple-sparing ma-
stectomy for an extended DCIS, without adjuvant ra-
diotherapy (RT) but with anti-aromatase hormone
treatment. In 3 cases we carried out an iterative con-
servative surgery and in 7 a simple mastectomy or skin
sparing.
Relapse after conservative surgery arose in 2 cases in
women also treated with adjuvant RT and in 4 women
who didn’t receive such treatment. The rate of local re-
lapse is lower for Van Nuys Prognostic Index (UNPI) 3
or 4 (5%) and higher for UNPI 8 or 9 (60%). We didn’t
find any new tumours at the controlateral breast.
Concerning treatment with tamoxifen or aromata-
se inhibitors, all women who received hormone treat-
ment had a positivity for hormone receptors. Preferen-
ce for tamoxifen treatment and LH-RH inhibitors
went to premenopausal women; aromatase treatments
were advised to women gone through menopause. 
Discussion 
About 80-90% of the patients currently treated for
DCIS present non-palpable breast lesions at diagnosis.
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Though mammography has 88% sensibility and a 10-
60% specificity, it undervalues the real extension of
these lesions in 46% of cases and often it doesn’t loca-
te multifocality. 
The breast Magnetic Resonance (MR), comple-
mentary to mammography and ecography, thanks to
its high sensibility (94-100%) and negative predictive
value (~100%), better defines dimensions and number
of the lesions, allowing to either identify or exclude
multifocality, multicentricity and controlateral lesions
(4). Furthermore it is the best detail methodology to
evaluate those lesions already identified by the mam-
mography, of which elevates sensibility (up to 90%)
and specificity (up to 98%) (5, 6). It also values the
ETC (extended intraductal component) which repre-
sents a fundamental parameter in the presurgical pene-
trating balance (10).
The limits of this methodology are represented by
the low specificity (37-86%) and by the impossibility
of predicting any possible penetrating component of
the carcinoma. For this parameter is then necessary to
resort to “core biopsy” (CB) which, in pre-surgical dia-
gnosis of breast lesions, allows a reliable histological
diagnosis, except for limited sampling. CB allows to
have a histological diagnosis of malignity either in situ
or invasive at least in 95% of palpable carcinoma and
in 90% of non-palpable ones (there are still uncertain
cases due to malignity represented by ductal and/or lo-
bular atypical epithelial hyperplasia, by papillary le-
sions, by philloides tumour and by radial scar or scle-
ro-elastic lesions), as well as the possibility of evalua-
ting histotype and histological grading.
The only disadvantage is linked to the impossibility
of studying the real extension of the neoplasia, which
remains prerogative of excisional biopsy. As in 90% of
the cases it appears with micro calcifications associated
to opacity and/or a parenchyma distortion non clini-
cally palpable, it’s possible to opt for a excisional biopsy
making use of three “centring” methods, besides skin
mapping (9):
- metallic guide;
- colouring agent;
- ROLL: Radio-guided Occult Lesion Localiza-
tion.
The advantage of ROLL is that one only intralesional
injection can identify the sentinel lymph node in 97%
of the cases, with a complete excision of the tumour of
87% (11).
The DCIS surgical management goes from mastec-
tomy to local excision followed by radiotherapy, right
to surgical excision (1). The type of treatment differs
according to the clinico-radiological pre-surgical fin-
dings (clinically palpable lump, microcalcifications or
opacity) and whether a cyto-histological data is availa-
ble or not.
With the only excision the risk of relapse increases
unacceptably even when the resection margins are >1
cm and the neoplasia presents a reduced degree, i.e.1-2
degree (12), considering that for tumours <2,5 cm is
possible that the micro infiltration is confirmed in 2%
of the cases. The characteristics that lead towards a pos-
sible DCIS invasivity are: comedo forms, high-degree
dysplasia, extended lesions, and presence of a mass (13-
15).
Different is what emerges from the mastectomy and
conservative surgery comparative study with RT, with
superimposable local relapse percentage and survival:
respectively 90% vs. 89% and 100% vs. 89%. Risk fac-
tors are: young age (<45 years), positive margins (<2
mm), missed RT, boost <9MeV, grade 3 (16). On the
basis of these factors, the adjuvant radiotherapic treat-
ment was proposed in those woman having high grade
comedonic DCIS with palpable mass or widely exten-
ded (17-20).
The guidelines about lymph nodes of the axillary
cavity are still uncertain. The lymph node axillary dis-
section seems to be an unacceptable over treatment, as
lymphonodal metastasis are present only from 0 to 7%,
being even lower in case of pure DCIS. But as 20% of
DCIS present infiltrations of the basal membrane, it’s
now routine use to search the sentinel lymph node al-
so in patients at the initial phase of tumose evolution
(usually T < 3 cm with N0) with palpable mass and
with diffuse calcification areas, keeping the dissection
for positive cases only (21).
Conclusions
Ductal carcinoma in situ present some peculiarities
concerning diagnosis and treatment. Important aspects
are extension, histopathological classification, surgical
resection, adjuvant radio- and ormonotheraphy. 
About 80-90% of the patients currently treated for
DCIS present non-palpable breast lesions at diagnosis.
Mammography has 88% sensibility and 60% specifi-
city; magnetic resonance as complement to mammo-
graphy and echography has high sensibility (94-
100%) and identify or exclude multifocality, multi-
centricity and controlateral lesions (22-24). Core bio-
psy and Mammotome® microbiopsy allows a reliable
histological diagnosis but for studying the real exten-
sion of neoplastic lesion is preferible remain excisional
biopsy using centring methods (metallic guide,
ROLL). 
The DCIS surgical management goes from ma-
stectomy to local excision; in our experience we prefer
quadrantectomy with metodic control of free margins.
Guidelines about axillary lymph nodes are still uncer-
tain. We use to search the sentinel lymph node kee-
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ping the axillary lymphectomy for positive case only.
Adjuvant radiotherapic treatment was proposed to pa-
tients having high degree comedonic DCIS with pal-
pable mass or widely extended. Patients with positive
hormone receptors received hormone treatment. 
In conclusion treatment of DCIS is very difficult
and it is possible the risk of overtreatment in the surgi-
cal and adiuvant management (19). 
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